The purpose of this study is to determine if LCI699, thorough reductions in aldosterone, can lower BP in patients with Primary hyperaldosteronism.
Clinical Study
Summary
Study Name: Proof-of-concept for the Aldosterone Synthase Inhibitor LCI699 in Patients With Primary Hyperaldosteronism
Status: Completed
Conditions: Primary aldosteronism
Interventions: Drug: LCI699
Locations: Novartis Investigator Site, France, France
Study link: https://ClinicalTrials.gov/show/NCT00732771
To search for other studies by topic, location, or status, go to our Clinical Studies page.
